Perspective Therapeutics Inc’s recently made public that its Chief Executive Officer Spoor Johan M. acquired Company’s shares for reported $49384.0 on Mar 28 ’25. In the deal valued at $2.24 per share,22,026 shares were bought. As a result of this transaction, Spoor Johan M. now holds 59,383 shares worth roughly $0.12 million.
Then, Spoor Johan M. bought 4,650 shares, generating $10,288 in total proceeds. Upon buying the shares at $2.21, the Chief Executive Officer now owns 4,650 shares.
Before that, Williamson Robert F III bought 38,145 shares. Perspective Therapeutics Inc shares valued at $81,775 were divested by the Director at a price of $2.14 per share. As a result of the transaction, Williamson Robert F III now holds 108,982 shares, worth roughly $0.21 million.
H.C. Wainwright initiated its Perspective Therapeutics Inc [CATX] rating to a Buy in a research note published on March 13, 2025; the price target was $10. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in early March with a ‘”a Sector outperform”‘ rating. BofA Securities also remained covering CATX and has decreased its forecast on November 25, 2024 with a “Neutral” recommendation from previously “Buy” rating. UBS started covering the stock on October 24, 2024. It rated CATX as “a Buy”.
Price Performance Review of CATX
On Friday, Perspective Therapeutics Inc [AMEX:CATX] saw its stock jump 4.84% to $1.95. Over the last five days, the stock has gained 8.33%. Perspective Therapeutics Inc shares have fallen nearly -38.87% since the year began. Nevertheless, the stocks have fallen -87.17% over the past one year. While a 52-week high of $19.05 was reached on 01/24/25, a 52-week low of $1.60 was recorded on 04/09/25. SMA at 50 days reached $2.5966, while 200 days put it at $8.0003.
Levels Of Support And Resistance For CATX Stock
The 24-hour chart illustrates a support level at 1.8000, which if violated will result in even more drops to 1.6500. On the upside, there is a resistance level at 2.0500. A further resistance level may holdings at 2.1500. The Relative Strength Index (RSI) on the 14-day chart is 38.53, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1224, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 61.96%. Stochastics %K at 30.98% indicates the stock is a holding.
How much short interest is there in Perspective Therapeutics Inc?
A steep rise in short interest was recorded in Perspective Therapeutics Inc stocks on 2025-03-31, dropping by -0.2 million shares to a total of 5.71 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 5.91 million shares. There was a decline of -3.49%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 01, 2024 when Wedbush began covering the stock and recommended ‘”an Outperform”‘ rating along with a $25 price target.
